SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-135211
Filing Date
2018-04-26
Accepted
2018-04-26 17:21:56
Documents
5
Period of Report
2018-06-12
Effectiveness Date
2018-04-26

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT d577168ddef14a.htm DEF 14A 271110
2 GRAPHIC g577168g01m68.jpg GRAPHIC 31200
3 GRAPHIC g577168g08c20.jpg GRAPHIC 36896
4 GRAPHIC g577168page003.jpg GRAPHIC 158859
5 GRAPHIC g577168page004.jpg GRAPHIC 136849
  Complete submission text file 0001193125-18-135211.txt   773416
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36183 | Film No.: 18779802
SIC: 2836 Biological Products, (No Diagnostic Substances)